Johnson & Johnson will acquire Firefly Bio for $1 billion in cash to access its degrader antibody conjugate platform and broaden its oncology pipeline. The deal adds novel targeted degradation technology aimed at accelerating J&J’s cancer drug development and diversifying its immuno-oncology portfolio.
Johnson & Johnson will pay $1 billion in cash to acquire Firefly Bio, securing its degrader antibody conjugate platform to strengthen J&J’s targeted cancer therapy offerings.
Firefly Bio’s technology enables targeted protein degradation of cancer drivers, complementing J&J’s existing immuno-oncology assets and addressing resistance seen with current therapies.
The transaction will be funded from existing cash reserves and is expected to close later this year following customary regulatory approvals, with limited impact on J&J’s leverage.
J&J will integrate Firefly’s R&D teams into its oncology division, initiate preclinical studies combining the degrader platform with internal candidates, and outline clinical development milestones.
Finance
